The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations

Opinion
Video

Panelists discuss how a patient and their medical team collaborated to evaluate the differences between ide-cel and cilta-cel CAR T therapies to make an informed treatment decision.

Video content above is prompted by the following:

  • Please walk us through the process of shared decision-making between you and your health care team. How did you decide between ide-cel and cilta-cel?
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
Related Content
Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Tim Cortese
January 9th 2025
Article

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma

CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma

ONCOLOGY Staff
December 30th 2024
Article

During the 2024 IMS Annual Meeting, colleagues gathered to discuss the latest advancements in multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

Arlo-cel Shows Promising Efficacy in Pretreated R/R Multiple Myeloma

Gina Mauro
December 27th 2024
Article

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma

Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma

ONCOLOGY Staff
December 26th 2024
Article

Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.